other material
confidence high
sentiment positive
materiality 0.70
Inhibrx reports ozekibart Phase 1 CRC data: 40% ORR, median PFS 7.85 months
Inhibrx Biosciences, Inc.
- 1 CR, 3 PR among 10 evaluable patients; median PFS of 7.85 months.
- Durable disease control ≥180 days observed in 46.2% of treated patients.
- Grade ≥3 TEAEs in 30.8% of patients; most AEs mild to moderate.
- Expansion cohort enrolling up to 50 patients, data expected Q3 2025.
- Two PRs occurred in patients who had failed prior FOLFIRI-based therapy.